[Treatment of extensive disease].
In locally advanced inoperable patients and metastatic patients imatinib is a standard treatment. Standard dose of imatinib is 400 mg daily. Treatment should be continued indefinitely, since treatment interruption is generally followed by relatively rapid tumor progression in virtually all patients. Dose intensity should be maintained by adequate management of side effects and a correct policy of dose reductions and interruptions in the case of excessive toxicity. The standard approach in the case of tumor progression is to increase the imatinib dose to 800 mg daily with special attention to the occurrence of side effects. Patient non-compliance should be ruled out as a possible cause of tumor progression as well as drug interactions with concomitant medications. In case of progression or intolerance to imatinib standard second-line treatment is sunitinib. The drug was approved effective in terms of progression-free survival according to a 4 weeks on and 2 weeks off regimen. Preliminary data show that a continuous regimen with lower daily dose may be equally effective but possibly better tolerated. After failing on sunitinib, the patient should be considered for participation in a clinical trial of new therapeutic agents or combinations such as tyrosine-kinase inhibitors (e.g., nilotinib), sorafenib, or inhibitors of the mTOR (mammalian target of rapamycin)-pathway.
Ploner
Ferdinand
F
Klinische Abteilung für Onkologie, Universitätsklinik für Innere Medizin, Medizinische Universität Graz, Graz, Austria.
Eisterer
Wolfgang
W
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001549:Benzamides; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000556:secondary; D006801:Humans; D000068877:Imatinib Mesylate; D007211:Indoles / Q000008:administration & dosage* / Q000009:adverse effects; D008134:Long-Term Care; D009361:Neoplasm Invasiveness; D010879:Piperazines / Q000008:administration & dosage* / Q000009:adverse effects; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects; D011758:Pyrroles / Q000008:administration & dosage* / Q000009:adverse effects; D000077210:Sunitinib
D000970:Antineoplastic Agents; D001549:Benzamides; D007211:Indoles; D010879:Piperazines; D011743:Pyrimidines; D011758:Pyrroles; D000068877:Imatinib Mesylate; C498826:nilotinib; D000077210:Sunitinib
Eur J Cancer. 2008 Mar;44(4):501-9
18234488
Eur J Cancer. 2006 May;42(8):1093-103
16624552
Lancet. 2006 Oct 14;368(9544):1329-38
17046465
Eur J Cancer. 2005 Aug;41(12):1751-7
16098458
Curr Oncol Rep. 2008 Jul;10(4):344-9
18778561
J Clin Oncol. 2009 Jul 1;27(19):3141-7
19451435
J Clin Oncol. 2008 Nov 20;26(33):5360-7
18955451
Recent Pat Anticancer Drug Discov. 2008 Jun;3(2):88-99
18537751
J Clin Oncol. 2008 Feb 1;26(4):626-32
18235122
Eur J Cancer. 2009 Jul;45(11):1959-68
19282169
Hum Pathol. 2002 May;33(5):466-77
12094371
Lancet. 2001 Oct 27;358(9291):1421-3
11705489
N Engl J Med. 2002 Aug 15;347(7):472-80
12181401
J Clin Oncol. 2007 Mar 20;25(9):1107-13
17369574
Science. 1998 Jan 23;279(5350):577-80
9438854
Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34
15451219
Ann Med. 2001 Oct;33(7):451-5
11680792
J Clin Oncol. 2003 Dec 1;21(23):4342-9
14645423
Pharmacology. 2006;77(1):11-6
16534250
J Clin Oncol. 2008 Feb 1;26(4):620-5
18235121